MEDIROM Healthcare Technologies (MRM)
NASDAQ:MRM
Top Page
MEDIROM Healthcare Technologies
(NASDAQ:MRM)
Select Model
Select Model
Rating:58Neutral
Price Target:
$1.50
▼(-22.28% Downside)
Action:ReiteratedDate:11/04/25
The overall stock score is primarily influenced by financial performance and technical analysis. While the company shows strong revenue growth, profitability and liquidity challenges are significant concerns. The technical indicators suggest a bearish trend, but the stock appears undervalued based on its P/E ratio.
Positive Factors
Recurring & Diversified Revenue Model
MEDIROM’s mix of tiered telemedicine subscriptions, product sales and service agreements builds recurring and diversified revenues. That business model provides predictable cash inflows, cross-sell opportunities and resilience versus single-product firms, supporting steadier medium-term growth.
Negative Factors
High Leverage / Low Equity Ratio
A low equity ratio and material debt-to-equity indicate heavy reliance on debt financing. Elevated leverage raises interest expense and refinancing sensitivity, limiting strategic flexibility and increasing solvency risk if operational performance weakens over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring & Diversified Revenue Model
MEDIROM’s mix of tiered telemedicine subscriptions, product sales and service agreements builds recurring and diversified revenues. That business model provides predictable cash inflows, cross-sell opportunities and resilience versus single-product firms, supporting steadier medium-term growth.
Read all positive factors
MEDIROM Healthcare Technologies (MRM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.69M
Dividend YieldN/A
Average Volume (3M)4.82M
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue Growth13.71%
EPS GrowthN/A
CountryUS
Employees334
SectorConsumer Cyclical
Sector Strength84
IndustryPersonal Products & Services
Share Statistics
EPS (TTM)-0.59
Shares Outstanding7,901,950
10 Day Avg. Volume3,803,708
30 Day Avg. Volume4,821,025
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)0.89
Price to Sales (P/S)0.10
P/FCF Ratio-0.44
Enterprise Value/Market Cap3.74
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda0.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MEDIROM Healthcare Technologies Business Overview & Revenue Model
Company Description
MEDIROM Healthcare Technologies Inc. provides holistic healthcare services in Japan. It operates in two segments, Relaxation Salon and Digital Preventative Healthcare. The Relaxation Salon segment owns and franchises relaxation salons, which provi...
How the Company Makes Money
MEDIROM Healthcare Technologies generates revenue through multiple channels, including subscription fees for its telemedicine services, sales of wellness and diagnostic products, and partnerships with healthcare providers and institutions. The com...
MEDIROM Healthcare Technologies Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.85B | 8.30B | 6.83B | 6.95B | 5.41B | 3.34B |
| Gross Profit | 1.67B | 2.25B | 1.57B | 1.90B | 1.42B | 428.95M |
| EBITDA | 825.29M | 387.50M | 310.08M | 373.63M | -276.29M | -551.16M |
| Net Income | 726.29M | 148.76M | 115.05M | 148.97M | -990.73M | -539.17M |
Balance Sheet | ||||||
| Total Assets | 55.36M | 8.09B | 6.85B | 6.75B | 5.75B | 5.71B |
| Cash, Cash Equivalents and Short-Term Investments | 268.75K | 335.56M | 132.85M | 605.95M | 377.12M | 1.47B |
| Total Debt | 27.12M | 3.96B | 3.65B | 3.23B | 2.79B | 2.56B |
| Total Liabilities | 51.91M | 6.90B | 6.63B | 6.81B | 5.96B | 5.22B |
| Stockholders Equity | 3.07M | 933.27M | 210.88M | -59.38M | -208.34M | 491.26M |
Cash Flow | ||||||
| Free Cash Flow | -1.09B | -1.90B | -767.58M | -806.44M | -652.88M | -439.98M |
| Operating Cash Flow | -548.33M | -1.33B | -631.74M | -685.70M | -557.23M | -366.42M |
| Investing Cash Flow | -402.10M | 361.39M | -328.58M | 580.44M | -83.94M | -139.60M |
| Financing Cash Flow | 1.13B | 1.19B | 461.21M | 340.10M | -427.95M | 1.43B |
MEDIROM Healthcare Technologies Technical Analysis
Negative
1.93
Price Trends
1.33
Negative
1.67
Negative
1.74
Negative
Market Momentum
-0.07
Negative
27.55
Positive
38.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRM, the sentiment is Negative. The current price of 1.93 is above the 20-day moving average (MA) of 1.20, above the 50-day MA of 1.33, and above the 200-day MA of 1.74, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 27.55 is Positive, neither overbought nor oversold. The STOCH value of 38.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MRM.
MEDIROM Healthcare Technologies Risk Analysis
MEDIROM Healthcare Technologies disclosed 60 risk factors in its most recent earnings report. MEDIROM Healthcare Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
ADSs representing our common shares are listed on the Nasdaq Capital Market. As such, we must meet the Nasdaq Capital Market's continued listing requirements and other Nasdaq rules, or we may risk delisting. Delisting could negatively affect the price of our ADSs, which could make it more difficult for us to sell securities in a financing and for you to sell your ADSs. Q4, 2022
2.
Sale of our salons could depend heavily on a number of factors, and as a result, our annual revenue from sale of salons may vary from year on year. Q4, 2022
MEDIROM Healthcare Technologies Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
58 Neutral | $8.69M | -0.60 | 48.22% | ― | 13.71% | ― | |
52 Neutral | $61.82M | 37.76 | 71.09% | ― | 13.98% | 34.14% | |
| ― | $6.30M | -51.23 | -1.53% | ― | -2.53% | 99.45% | |
45 Neutral | $10.02M | -0.07 | ― | ― | ― | ― |
* Consumer Cyclical Sector Average
MRM
MEDIROM Healthcare Technologies
1.10
0.58
111.54%
RGS
Regis
24.74
7.78
45.87%
EJH
E-Home Household Service Holdings
1.97
-1,385.53
-99.86%
YYGH
YY Group Holding Limited Class A
1.08
-58.42
-98.18%
MEDIROM Healthcare Technologies Corporate Events
MEDIROM Strikes Major World ID Deal to Roll Out Orb Devices Across 3,000 Sites in Japan
Jan 23, 2026
On January 23, 2026, MEDIROM Healthcare Technologies Inc. signed a Master Service Agreement with Tools for Humanity and the World Foundation to support large-scale adoption of World ID in Japan by installing Orb biometric authentication devices at...
MEDIROM, World ID Authentications Double to 20,000 at Re.Ra.Ku Salons in Two Months
Jan 8, 2026
On January 8, 2026, MEDIROM Healthcare Technologies announced that its collaboration with World, the Proof of Human authentication protocol co-founded by Sam Altman and Alex Blania, helped drive the cumulative number of World ID “Orb” ...
MEDIROM to Build World’s ‘Proof of Human’ Network Across Japan Under New Service Pact
Dec 29, 2025
On December 29, 2025, MEDIROM Healthcare Technologies announced it had signed a Master Service Agreement with Tools for Humanity and the World Foundation to build and operate a “Proof of Human” verification network in Japan, based on t...
MEDIROM Posts Strong November KPIs With Higher Customer Loyalty and Growth in Lav® Health-Tech Users
Dec 22, 2025
On December 22, 2025, MEDIROM Healthcare Technologies reported key performance indicators for November 2025, highlighting solid salon economics despite a modest contraction in scale. The company operated 294 salons, with data from 273 locations sh...
MEDIROM Healthcare Technologies Completes JPY400 Million Bond Issuance
Dec 15, 2025
On December 12, 2025, MEDIROM Healthcare Technologies Inc. completed the sale and issuance of JPY400,000,000 in convertible corporate bonds to 11 investors. The proceeds will be used for general corporate and financing purposes. The bonds were iss...
MEDIROM Healthcare Technologies Issues Convertible Bonds to Boost Financial Flexibility
Dec 12, 2025
On December 11, 2025, MEDIROM Healthcare Technologies Inc. announced the issuance of its Third Unsecured Convertible-Type Corporate Bonds with Share Options, totaling 400,000,000 JPY. The bonds, issued through a third-party allotment, are set to c...
MEDIROM Partners with TD SYNNEX for National Expansion of Health-Tech Solutions
Dec 4, 2025
On December 4, 2025, MEDIROM Healthcare Technologies Inc. announced a strategic partnership with TD SYNNEX K.K. to enhance the national distribution of the MOTHER Bracelet and REMONY health monitoring system. This collaboration aims to leverage TD...
MEDIROM Healthcare Technologies Reports Strong October 2025 KPIs
Dec 3, 2025
On December 3, 2025, MEDIROM Healthcare Technologies Inc. announced its updated Key Performance Indicators (KPIs) for October 2025. The company reported serving 69,669 customers with a sales per customer figure of JPY 7,445, significantly higher t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.